341 related articles for article (PubMed ID: 27174537)
1. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
Löppenberg B; Dalela D; Karabon P; Sood A; Sammon JD; Meyer CP; Sun M; Noldus J; Peabody JO; Trinh QD; Menon M; Abdollah F
Eur Urol; 2017 Jul; 72(1):14-19. PubMed ID: 27174537
[TBL] [Abstract][Full Text] [Related]
2. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
3. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
[TBL] [Abstract][Full Text] [Related]
4. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
5. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
Vetterlein MW; Löppenberg B; Karabon P; Dalela D; Jindal T; Sood A; Chun FK; Trinh QD; Menon M; Abdollah F
Cancer; 2017 Sep; 123(17):3241-3252. PubMed ID: 28472547
[TBL] [Abstract][Full Text] [Related]
6. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
[TBL] [Abstract][Full Text] [Related]
7. Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis.
Liu S; Wang XY; Huang TB; Niu Q; Yao K; Song X; Zhou SY; Chen Z; Zhou GC
Ann Palliat Med; 2020 Jul; 9(4):1708-1717. PubMed ID: 32527134
[TBL] [Abstract][Full Text] [Related]
8. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.
Nepple KG; Stephenson AJ; Kallogjeri D; Michalski J; Grubb RL; Strope SA; Haslag-Minoff J; Piccirillo JF; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Kibel AS
Eur Urol; 2013 Sep; 64(3):372-8. PubMed ID: 23506834
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
Pompe RS; Tilki D; Preisser F; Leyh-Bannurah SR; Bandini M; Marchioni M; Gild P; Tian Z; Fossati N; Cindolo L; Shariat SF; Huland H; Graefen M; Briganti A; Karakiewicz PI
Prostate; 2018 Jul; 78(10):753-757. PubMed ID: 29663462
[TBL] [Abstract][Full Text] [Related]
10. Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder.
Vetterlein MW; Karabon P; Dalela D; Jindal T; Sood A; Seisen T; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2018 Jul; 4(4):568-571. PubMed ID: 28753834
[TBL] [Abstract][Full Text] [Related]
11. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
12. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
[TBL] [Abstract][Full Text] [Related]
13. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
14. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y
Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983
[TBL] [Abstract][Full Text] [Related]
15. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
16. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.
Abdollah F; Suardi N; Cozzarini C; Gallina A; Capitanio U; Bianchi M; Sun M; Fossati N; Passoni NM; Fiorino C; Di Muzio N; Karakiewicz PI; Rigatti P; Montorsi F; Briganti A
Eur Urol; 2013 Jun; 63(6):998-1008. PubMed ID: 23122664
[TBL] [Abstract][Full Text] [Related]
17. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.
Lee JY; Kang HW; Rha KH; Cho NH; Choi YD; Hong SJ; Cho KS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):849-58. PubMed ID: 26660495
[TBL] [Abstract][Full Text] [Related]
18. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
19. Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
Fosså SD; Wiklund F; Klepp O; Angelsen A; Solberg A; Damber JE; Hoyer M; Widmark A;
Eur Urol; 2016 Oct; 70(4):684-691. PubMed ID: 27025586
[TBL] [Abstract][Full Text] [Related]
20. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
